December 11, 2020

Comparison of Estimated SARS-CoV-2 Seroprevalence through Commercial Laboratory Residual Sera Testing and a Community Survey

Category: Article Summary

Topic: Testing and Treatment

Keywords (Tags): testing

• Estimates of seroprevalence of antibodies against SARS-CoV-2 among residents of metropolitan Atlanta during April-May 2020 ranged from 4.9% to 3.2%. These estimates were based on antibody tests conducted on residual sera from commercial laboratory samples (4.9% seroprevalence) and a community household survey (3.2% seroprevalence). Compared with more representative surveys, the authors conclude that that commercial sera can provide an approximate measure of seroprevalence.

Bajema et al. (Dec 10, 2020). Comparison of Estimated SARS-CoV-2 Seroprevalence through Commercial Laboratory Residual Sera Testing and a Community Survey. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciaa1804